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ABSTRACT
Objective: To evaluate the pharmacokinetics and cost of once-daily dosing with gentamicin in
women with postpartum endometritis.
Methods: Gentamicin in a single daily dose of 4.5 mg/kg was administered intravenously to 10
women with postpartum endometritis. Peak and trough gentamicin levels were measured, and
nephrotoxicity and clinical ototoxicity were monitored. Pharmacokinetic data were analyzed, and
a cost analysis of once-daily gentamicin administration was performed.
Results: The mean elimination constant was 0.105 0.008 L/h, and the mean volume of distri-
bution was 0.34 0.07 L/kg. Mean peak gentamicin levels exceeded 11 mg/L, and all trough levels
were <0.3 mg/L. Cost savings of44% were achieved with once-daily dosing ofgentamicin, compared
with traditional thrice-daily dosing.
Conclusions: Once-daily dosing with gentamicin in women with postpartum endometritis achieves
therapeutic peak levels without drug accumulation. Substantial cost savings are realized with this
dosing regimen. Infect. Dis. Obstet. Gynecol. 6:160-162, 1998. (C) 1998 Wiley-Liss, Inc.
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entamicin remains a popular bacteriocidal an-
tibiotic for the treatment of infections caused
by gram-negative organisms. Postpartum endome-
tritis, typically a polymicrobial infection of both
aerobic and anaerobic organisms, is often treated
with clindamycin and gentamicin for broad-
spectrum coverage. While it is a highly effective
antibiotic, gentamicin is associated with potentially
serious toxicity, including nephrotoxicity and oto-
toxicity. A review of prospective clinical trials of
adult patients treated with aminoglycosides be-
tween 1975 and 1982 indicated that the average
frequencies of nephrotoxicity and ototoxicity of
gentamicin are 14% and 8%, respectively. More-
over, wide variations in dosage requirements of
gentamicin have been demonstrated in the post-
partum period, and subtherapeutic levels are seen
in one third of women receiving standard dosing
regimens, e,3
Aminoglycosides are commonly administered in
either two or three divided doses per day. Two
properties of aminoglycoside agents, the postanti-
biotic effect (PAE) and concentration-dependent
killing, have raised interest in the idea of less fre-
quent dosing of aminoglycosides. Postantibiotic ef-
fect is defined as ongoing bacterial inhibition after
the antibiotic exposure has ceased. As such, the
efficacy of aminoglycosides may not rely on main-
taining serum concentrations above the minimum
inhibitory concentration.4 The duration of the PAE
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correlates with the aminoglycoside concentration.
Aminoglycoside antibiotics exhibit concentration-
dependent bactericidal activity, with greater anti-
bacterial activity seen in higher doses of the
drug.4,s In addition, a once-daily dosing regimen of
aminoglycoside antibiotics may result in less drug
accumulation in the renal cortex, thereby poten-
tially decreasing nephrotoxicity. We report on the
pharmacokinetics and cost of once-daily dosing
with gentamicin in postpartum women with endo-
mctritis.
SUBJECTS AND METHODS
Women 18 years of age and older with postpartum
cndometritis were eligible for the study and were
enrolled between July 1995 and January 1996. This
study was approved by the institutional review
board. The diagnosis of cndomctritis was based on
temperature elevation greater than 38 C and uter-
ine tenderness occurring at least 24 hours postpar-
tum in the absence of any other source of infection.
Exclusion criteria included aminoglycoside allergy,
renal impairment (defined as serum creatininc > 1.2
mg/dL or estimated creatininc clearance <60 mL/
min), known hearing loss, or immunocompromised
status. After obtaining informed consent, patients
were administered a single dose of gentamicin at a
dose of 4.5 mg per kilogram of actual body weight
over 30 minutes every 24 hours. Gentamicin was
used in combination with clindamycin to provide
polymicrobial coverage. Blood urea nitrogen and
creatinine were determined prior to initiation of
therapy and every 48 hours during treatment.
Nephrotoxicity was defined as an elevation of se-
rum creatinine from baseline greater than 0.5 mg/
dL. Gentamicin levels were drawn 30 minutes after
completion of the first and second doses, 30 min-
utes prior to the second and third doses, and an
8-hour level was drawn after the second dose. Phar-
macokinetic data were analyzed for each patient
using standard pharmacokinetic principles.6 Oto-
toxicity was evaluated clinically by regularly ques-
tioning patients about hearing loss, tinnitus, and
vertigo. No audiometric evaluations were per-
formed.
Cost analysis was based on 72 hours of treatment
using 300 mg/d of gentamicin in the once-daily
regimen compared with 100 mg every 8 hours in
the traditional dosing regimen. Patient charges
from the pharmacy for preparation and dispensing
TABLE !. Demographic and pharmacokinetic data
Characteristic Mean + SD Range
Age (y) 26.2 + 8.4 18-41
Weight (kg) 80.3 + 23.9 56-136
Dose (mg) 360 + 105 255-600
Half life (h) 4.36 + 0.22 3.96-4.67
Estimated clearance (mL/min) 149 + 53 84-271
"SD, standard deviation.
and nursing administration times were calculated.
Nursing costs were based on hospital costs and
were determined using an average registered nurse
wage of $18/h. Charges for intravenous tubing and
gentamicin level monitoring were excluded in the
cost analysis, as intravenous tubing costs are mini-
mal, and gentamicin level monitoring may be nec-
essary with both single and thrice-daily treatment
regimens.
Gentamicin serum concentrations were deter-
mined by fluorescence polarization immunoassay
using an automated fluorescence polarization ana-
lyzer. (Abbott Diagnostics, Abbott Park, IL). For
levels between 2 and 5 mg/L, the coefficient of
variation was 5%. Levels between 10 and 15 mg/L
had a coefficient of variation of 6%.
RESULTS
Ten women with postpartum endometritis were
enrolled in this study. Table summarizes demo-
graphic data as well as half life and estimated cre-
atinine clearance. The mean (_+ standard deviation
[SD]) elimination constant was 0.105 _+ 0.008 L/h,
with a range of 0.096-0.122 L/h. The mean volume
of distribution (+_ SD) was 0.34 + 0.07 L/kg, with a
range of 0.27-0.51 L/kg. The mean first peak level
(_+ SD) was 11.6 _+ 2.3 mg/L. The mean second
peak level (+ SD) was 13.0 + 2.5 mg/L. All first and
second trough levels were less than 0.3 mg/L. A
favorable clinical response was seen in nine pa-
tients. The median duration of therapy was 3 days.
One patient was administered heparin therapy for
presumed septic pelvic thrombophlebitis. There
was no nephrotoxicity nor clinical ototoxicity de-
tected.
Based on a 3-day course of gentamicin, the pa-
tient charge from our pharmacy for the once-daily
regimen was $241, compared with $422 for the
thrice-daily regimen. After adding nursing admin-
istration times, the total patient charges were $250
and $449 respectively. This represents a 44% re-
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duction in patient charges for the once-daily regi-
men when compared with the thrice-daily regimen
for 72 hours of treatment.
DISCUSSION
This study demonstrates several important points
regarding a once-daily dose of gentamicin among
postpartum women. Our data show that no drug
accumulation occurred during our treatment pe-
riod, as trough levels were consistently less than 0.3
mg/L. This is important clinically as data suggests
that aminoglycoside-free periods during therapy
are necessary to reduce the risk of nephrotoxicity
and ototoxicity. 7 We were also able to consistently
achieve elevated peak levels with our dosing regi-
men, optimizing the PAE and concentration-
dependent killing characteristics of aminoglycoside
antibiotics. 7 Our pharmacokinetic parameters were
consistent with published data from Sangha et al.
evaluating once-daily dosing with gentamicin in in-
tensive care unit patients with open fractures,s The
numerous physiologic changes that occur during
the postpartum period may cause wide fluctuations
in the pharmacokinetic parameters. This may ex-
plain the differences in elimination rate constant,
volume of distribution, and half life between our
data and those reported recently by Del Priore et
al.9 An additional factor that may reflect a higher
half life is that our laboratory could not detect gen-
tamicin levels less than 0.3 rag/L, the trough value
used to calculate the half life. Higher trough levels
lengthen the half life. Finally, we were able to
demonstrate significant cost savings with a once-
daily regimen in the postpartum patient with en-
dometritis, reducing charges by nearly one half.
The results of this study support the conclusions of
two reports of once-daily gentamicin in the treat-
ment of puerperal uterine infections.9,1 Once-
daily dosing of gentamicin for the treatment of
postpartum endometritis is efficacious and cost-
effective, and it appears that this regimen is not
associated with a high incidence of nephrotoxicity
or ototoxicity.
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